[Code of Federal Regulations]
[Title 21, Volume 8]
[Revised as of April 1, 2008]
From the U.S. Government Printing Office via GPO Access
[CITE: 21CFR820.1]

[Page 146-148]
 
                        TITLE 21--FOOD AND DRUGS
 
CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN 
                          SERVICES (CONTINUED)
 
PART 820_QUALITY SYSTEM REGULATION--Table of Contents
 
                      Subpart A_General Provisions
 
Sec. 820.1  Scope.


    (a) Applicability. (1) Current good manufacturing practice (CGMP) 
requirements are set forth in this quality system regulation. The 
requirements in this part govern the methods used in, and the facilities 
and controls used for, the design, manufacture, packaging, labeling, 
storage, installation,

[[Page 147]]

and servicing of all finished devices intended for human use. The 
requirements in this part are intended to ensure that finished devices 
will be safe and effective and otherwise in compliance with the Federal 
Food, Drug, and Cosmetic Act (the act). This part establishes basic 
requirements applicable to manufacturers of finished medical devices. If 
a manufacturer engages in only some operations subject to the 
requirements in this part, and not in others, that manufacturer need 
only comply with those requirements applicable to the operations in 
which it is engaged. With respect to class I devices, design controls 
apply only to those devices listed in Sec. 820.30(a)(2). This 
regulation does not apply to manufacturers of components or parts of 
finished devices, but such manufacturers are encouraged to use 
appropriate provisions of this regulation as guidance. Manufacturers of 
human blood and blood components are not subject to this part, but are 
subject to part 606 of this chapter. Manufacturers of human cells, 
tissues, and cellular and tissue-based products (HCT/Ps), as defined in 
Sec. 1271.3(d) of this chapter, that are medical devices (subject to 
premarket review or notification, or exempt from notification, under an 
application submitted under the device provisions of the act or under a 
biological product license application under section 351 of the Public 
Health Service Act) are subject to this part and are also subject to the 
donor-eligibility procedures set forth in part 1271 subpart C of this 
chapter and applicable current good tissue practice procedures in part 
1271 subpart D of this chapter. In the event of a conflict between 
applicable regulations in part 1271 and in other parts of this chapter, 
the regulation specifically applicable to the device in question shall 
supersede the more general.
    (2) The provisions of this part shall be applicable to any finished 
device as defined in this part, intended for human use, that is 
manufactured, imported, or offered for import in any State or Territory 
of the United States, the District of Columbia, or the Commonwealth of 
Puerto Rico.
    (3) In this regulation the term ``where appropriate'' is used 
several times. When a requirement is qualified by ``where appropriate,'' 
it is deemed to be ``appropriate'' unless the manufacturer can document 
justification otherwise. A requirement is ``appropriate'' if 
nonimplementation could reasonably be expected to result in the product 
not meeting its specified requirements or the manufacturer not being 
able to carry out any necessary corrective action.
    (b) The quality system regulation in this part supplements 
regulations in other parts of this chapter except where explicitly 
stated otherwise. In the event of a conflict between applicable 
regulations in this part and in other parts of this chapter, the 
regulations specifically applicable to the device in question shall 
supersede any other generally applicable requirements.
    (c) Authority. Part 820 is established and issued under authority of 
sections 501, 502, 510, 513, 514, 515, 518, 519, 520, 522, 701, 704, 
801, 803 of the act (21 U.S.C. 351, 352, 360, 360c, 360d, 360e, 360h, 
360i, 360j, 360l, 371, 374, 381, 383). The failure to comply with any 
applicable provision in this part renders a device adulterated under 
section 501(h) of the act. Such a device, as well as any person 
responsible for the failure to comply, is subject to regulatory action.
    (d) Foreign manufacturers. If a manufacturer who offers devices for 
import into the United States refuses to permit or allow the completion 
of a Food and Drug Administration (FDA) inspection of the foreign 
facility for the purpose of determining compliance with this part, it 
shall appear for purposes of section 801(a) of the act, that the methods 
used in, and the facilities and controls used for, the design, 
manufacture, packaging, labeling, storage, installation, or servicing of 
any devices produced at such facility that are offered for import into 
the United States do not conform to the requirements of section 520(f) 
of the act and this part and that the devices manufactured at that 
facility are adulterated under section 501(h) of the act.
    (e) Exemptions or variances. (1) Any person who wishes to petition 
for an exemption or variance from any device quality system requirement 
is subject to the requirements of section 520(f)(2) of the act. 
Petitions for an exemption

[[Page 148]]

or variance shall be submitted according to the procedures set forth in 
Sec. 10.30 of this chapter, the FDA's administrative procedures. 
Guidance is available from the Center for Devices and Radiological 
Health, Division of Small Manufacturers, International and Consumer 
Assistance (HFZ-220), 1350 Piccard Dr., Rockville, MD 20850, U.S.A., 
telephone 1-800-638-2041 or 240-276-3150, FAX 240-276-3151.
    (2) FDA may initiate and grant a variance from any device quality 
system requirement when the agency determines that such variance is in 
the best interest of the public health. Such variance will remain in 
effect only so long as there remains a public health need for the device 
and the device would not likely be made sufficiently available without 
the variance.

[61 FR 52654, Oct. 7, 1996, as amended at 65 FR 17136, Mar. 31, 2000; 65 
FR 66636, Nov. 7, 2000; 69 FR 29829, May 25, 2005; 72 FR 17399, Apr. 9, 
2007]